A recent Executive Order (EO) de-risks psychedelic drug development by clarifying regulations, but scalable treatment models and rigorous data collection remain critical.
Building trust starts with connection. By engaging communities where they are, we can increase awareness, answer questions, and support more inclusive clinical research participation.
Explore how eSource is advancing clinical trials through smarter data capture, improved quality, faster execution, and more connected digital study operations.
Ensure long-term GxP compliance and audit readiness by centralizing fragmented records. Learn to preserve data integrity and reduce IT overhead while keeping vital information accessible.
Are your Phase I–III/IV clinical studies prepared for today's regulatory landscape? Learn how leading organizations are addressing compliance, transparency, and data ownership risks.
Peptide therapeutics from early chemical breakthroughs to today’s metabolic drugs, highlighting scientific, clinical, and manufacturing advances shaping modern drug development.
